Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis
Carregando...
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
MEXICAN ASSOC HEPATOLOGY
Autores
V, Jose Ramalho-Madruga
ALVES, Katia
NUNES, Estevao P.
CHEINQUER, Hugo
BRANDAO-MELLO, Carlos E.
FERRAZ, Maria L.
FERREIRA, Paulo R. A.
ALVARES-DA-SILVA, Mario R.
Citação
ANNALS OF HEPATOLOGY, v.17, n.6, p.959-968, 2018
Resumo
Introduction and aim. Approximately 650,000 people in Brazil have chronic hepatitis C virus (HCV) infection. We evaluated the safety and efficacy of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) plus dasabuvir (DSV) with/without ribavirin (RBV) in an openlabel multicenter phase 3b trial in treatment-naive or interferon (IFN) treatment-experienced Brazilian patients with advanced hepatic fibrosis (METAVIR F3/4) and HCV genotype (GT) 1 infection. Material and methods. All patients received coformulated OBV/PTV/r daily + DSV twice daily (3-DAA). GT1a-infected patients received 3-DAA plus RBV for 12 weeks, except for prior pegIFN/RBV nonresponders with cirrhosis who were treated for 24 weeks. GT1b-infected patients received 3-DAA alone (F3) or in combination with RBV (F4) for 12 weeks. The primary endpoint was sustained virologic response (HCV RNA < 15 IU/mL) at post-treatment Week 12 (SVR12). Results. The study enrolled 222 patients, 214 achieved an SVR 12 (96.4%; 95% CI, 93.1-98.2%), one GT1a-infected patient experienced virologic breakthrough, six (5 GT1a) relapsed, and one was lost to follow-up. SVR 12 was achieved in 111/112 (99.1%) GT1b-infected patients, including 42/43 (97.7%) noncirrhotic, and 69/69 (100%) cirrhotic patients; and in 103/110 (93.6%) GT1a-infected patients, including 44/46 (95.7%) noncirrhotic and 59/64 (92.2%) cirrhotic patients. Overall there was a low rate of serious adverse events (n = 6, 2.7%). One patient experienced a treatment-related serious adverse event and one patient discontinued treatment because of an adverse event. Discussion. The results confirm that the 3-DAA regimen with/without RBV is well tolerated and had a favorable safety profile and is efficacious in GT1-infected patients with advanced fibrosis (METAVIR F3/4).
Palavras-chave
Chronic hepatits C, Direct-acting antivirals, Genotype 1, Advanced fibrosis
Referências
- AASLD-IDSA Guidance Panel, HCV GUID REC TEST MA
- Amaku M, 2016, B MATH BIOL, V78, P970, DOI 10.1007/s11538-016-0170-4
- Andreone P, 2014, GASTROENTEROLOGY, V147, P359, DOI 10.1053/j.gastro.2014.04.045
- [Anonymous], 2017, PROTOCOLO CLINICO DI
- [Anonymous], COPEGUS RIBAVIRIN TA
- Barros Ricardo, 2017, WORLD HEPATITIS SUMM
- Blach S, 2017, LANCET GASTROENTEROL, V2, P161, DOI 10.1016/S2468-1253(16)30181-9
- Castro R, 2015, INT J HEPATOL, DOI 10.1155/2015/852968
- European Ass Study Liver, 2017, J HEPATOL, V66, P153, DOI 10.1016/j.jhep.2016.09.001
- Feld JJ, 2016, J HEPATOL, V64, P301, DOI 10.1016/j.jhep.2015.10.005
- Feld JJ, 2014, NEW ENGL J MED, V370, P1594, DOI 10.1056/NEJMoa1315722
- Ferenci P, 2014, NEW ENGL J MED, V370, P1983, DOI 10.1056/NEJMoa1402338
- Lawitz E, 2015, GASTROENTEROLOGY, V149, P971, DOI 10.1053/j.gastro.2015.07.001
- Omata M, 2016, HEPATOL INT, V10, P702, DOI 10.1007/s12072-016-9717-6
- Pereira LMMB, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-60
- Poordad F, 2014, NEW ENGL J MED, V370, P1973, DOI 10.1056/NEJMoa1402869
- Zeuzem S, 2014, NEW ENGL J MED, V370, P1604, DOI 10.1056/NEJMoa1401561